Exploring the potential of new combination therapy strategies in advanced gastric cancer

Conflict of interest

The authors declare they have no competing interests.

References

[1] Guan WL, He Y, Xu RH. Gastric cancer treatment: Recent progress and future perspectives. J Hematol Oncol. 2023; 16(1):57. doi: 10.1186/s13045-023-01451-3

[2] Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020; 396(10251):635-648. doi: 10.1016/s0140-6736(20)31288-5

[3] Akbas S, Alan O, Kuvvet BB, Lacin S, Köylü B, Selcukbiricik F. Nivolumab, ramucirumab and paclitaxel combination as second line therapy for advanced stage gastric cancer. EJMO. 2024; 8(4):488-495. doi: 10.14744/ejmo.2024.40834

[4] Nakajima TE, Kadowaki S, Minashi K, et al. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin Cancer Res. 2021; 27(4):1029-1036. doi: 10.1158/1078-0432.Ccr-20-3559

[5] Depotte L, Palle J, Rasola C, et al. New developments and standard of care in the management of advanced gastric cancer. Clin Res Hepatol Gastroenterol. 2024; 48(1):102245. doi: 10.1016/j.clinre.2023.102245

[6] Izawa N, Ohta S, Kadowaki S, et al. 104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC). Ann Oncol. 2020; 31:S282-S283. doi: 10.1016/j.annonc.2020.08.225

[7] Thuss-Patience P, Högner A, Goekkurt E, et al. Ramucirumab, avelumab, and paclitaxel as second-line treatment in esophagogastric adenocarcinoma: The phase 2 RAP (AIO-STO-0218) nonrandomized controlled trial. JAMA Netw Open. 2024; 7(1):e2352830. doi: 10.1001/jamanetworkopen.2023.52830

[8] Ye HN, Liu XY, Qin BL. Research progress of integrated traditional Chinese and Western medicine in the treatment of advanced gastric cancer. World J Gastrointest Oncol. 2023; 15(1):69-75. doi: 10.4251/wjgo.v15.i1.69

[9] Tan Y, Wang H, Xu B, et al. Chinese herbal medicine combined with oxaliplatin-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis of contributions of specific medicinal materials to tumor response. Front Pharmacol. 2022; 13:977708. doi: 10.3389/fphar.2022.977708

[10] Kong X, Li Q, Wang D, Wang M, Yang F, Meng J. Mechanism of qizhen decoction-mediated maturation of DC cells to activate the IL-12/JAK2/STAT4 pathway to sensitise PD-1 inhibitors in the treatment of colorectal cancer. J Ethnopharmacol. 2024; 320:117399. doi: 10.1016/j.jep.2023.117399